Aldo Peixoto is a Nephrology physician affiliated with Yale New Haven Hospital. OpenAlex indexes 146 publications with 4,638 citations (h-index 34); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Cedar St
Boardman 114
New Haven, CT 065191612
Telephone
203-785-4184Registry record last updated 29 Apr 2015.
Clinical trials
- Dialysate Sodium Individualization in Hemodialysis
Sponsor: Yale University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202414 payments
- Travere Therapeutics, Inc.Program year20241 payment
- Regeneron Pharmaceuticals, Inc.Program year20233 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.9%alpha-Adrenergic Agonist23.1%Midodrine Hcl100%Part D≥15 patientsCentral alpha-2 Adrenergic Agonist19.9%Clonidine62%Clonidine Hcl38%Part D<11 patients+ 5 more classes in this area
Nervous system
11.6%Benzodiazepine7.2%Alprazolam100%Part D<11 patientsOpioid Agonist4.4%Oxycodone Hcl100%Part D<11 patientsMetabolism & gastrointestinal
7.6%SGLT2 inhibitor7.6%Farxiga100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Annals of Internal Medicine
2023 - The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study
American Journal of Kidney Diseases
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Sanacora, MD, PhD
Yale New Haven Hospital
John Elefteriades, MD
Yale New Haven Hospital
Jeptha Curtis, MD
Yale New Haven Hospital
Erica Spatz, MD
Yale New Haven Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”